Big Data: Moving From Artificial Trials To A Smarter Regulatory Process
Executive Summary
This year the EU Big Data Task Force intends to deliver an EU-wide strategy on how big data can be used to support the development and evaluation of new medicines. The recent massive growth of data generated by various technologies, such as ‘omics, portable devices, the internet of things and even social media, gives this task force an urgency for pharma and regulators. Bruno Boulanger discusses the impact this will have on how the pharmaceutical industry gathers and delivers data in the future.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.